These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 28481792)
1. Multiparametric Evaluation of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer Using Integrated PET/MR. Wang J; Shih TT; Yen RF Clin Nucl Med; 2017 Jul; 42(7):506-513. PubMed ID: 28481792 [TBL] [Abstract][Full Text] [Related]
2. Integrated Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445 [TBL] [Abstract][Full Text] [Related]
3. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography. Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441 [TBL] [Abstract][Full Text] [Related]
5. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954 [TBL] [Abstract][Full Text] [Related]
7. Textural features of Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331 [TBL] [Abstract][Full Text] [Related]
8. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study. Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617 [TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA; J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256 [TBL] [Abstract][Full Text] [Related]
11. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935 [TBL] [Abstract][Full Text] [Related]
12. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy. Lee SM; Bae SK; Kim TH; Yoon HK; Jung SJ; Park JS; Kim CK Clin Nucl Med; 2014 Oct; 39(10):882-6. PubMed ID: 25072926 [TBL] [Abstract][Full Text] [Related]
13. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI. Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485 [TBL] [Abstract][Full Text] [Related]
14. Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning. Choi JH; Kim HA; Kim W; Lim I; Lee I; Byun BH; Noh WC; Seong MK; Lee SS; Kim BI; Choi CW; Lim SM; Woo SK Sci Rep; 2020 Dec; 10(1):21149. PubMed ID: 33273490 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of FDG-PET and DWI in breast cancer. Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K Ann Nucl Med; 2018 Jan; 32(1):44-53. PubMed ID: 29134565 [TBL] [Abstract][Full Text] [Related]
16. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT. An YY; Kim SH; Kang BJ; Lee AW J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936 [TBL] [Abstract][Full Text] [Related]
17. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490 [TBL] [Abstract][Full Text] [Related]
18. Complete Metabolic Response on Interim Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466 [TBL] [Abstract][Full Text] [Related]
19. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer. Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201 [TBL] [Abstract][Full Text] [Related]
20. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Chen BB; Tien YW; Chang MC; Cheng MF; Chang YT; Yang SH; Wu CH; Kuo TC; Shih IL; Yen RF; Shih TT Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1205-1217. PubMed ID: 29476229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]